How much revenue does Sinotherapeutics make?

Sinotherapeutics reported 446.57 million CNY in revenue for fiscal year 2025, down 12.7% from 511.62 million CNY in fiscal year 2024. In Q1 2026 revenue was 94.55 million CNY.

Where does Sinotherapeutics make most of its revenue?

China: 59% of revenue by region in fiscal year 2024, followed by Overseas (41%).

What companies are similar to Sinotherapeutics?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ), Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ), Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513.SS), Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ).

Sinotherapeutics Inc. (688247.SS) Stock

About Sinotherapeutics Inc.

Sinotherapeutics Inc., a specialty pharmaceutical company, research, develops, manufactures, and commercializes generic and formulation products in China. The company's products are indicated for infection, oncology and rheumatology, gastroenterology and metabolism, neurology, cardiology, and nephrology. It offers posaconazole delayed-release tablets; olaparib, exemestane, and tofacitinib extended...

At a glance

Sinotherapeutics reported revenue of 446.57 million CNY for fiscal year 2025, down 12.7% from fiscal year 2024, and net income of 47.48 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 94.55 million CNY, down 13.2% from a year before. China was its largest region in fiscal year 2024, with 59% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.